The specter of generic challenges has long loomed over copyright’s blockbuster drug, Viagra, raising questions about the prospects of similar drug holdings. While early times saw impressive returns, the exclusivity lapse has created the way for discounted substitutes, likely lowering earnings and presenting a real hazard for investors pursuing sa